| Attention deficit hyperactivity disorder
Jornay PM vs Qelbree
Side-by-side clinical, coverage, and cost comparison for attention deficit hyperactivity disorder.Deep comparison between: Jornay Pm vs Qelbree with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQelbree has a higher rate of injection site reactions vs Jornay Pm based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qelbree but not Jornay Pm, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jornay Pm
Qelbree
At A Glance
Oral
Daily
CNS stimulant
Oral
Once daily
Selective norepinephrine reuptake inhibitor
Indications
- Attention deficit hyperactivity disorder
- Attention deficit hyperactivity disorder
Dosing
Attention deficit hyperactivity disorder 20 mg once daily orally in the evening (between 6:30 p.m. and 9:30 p.m.) as the starting dose for patients 6 years and older; titrate weekly in increments of 20 mg up to a maximum of 100 mg/day.
Attention deficit hyperactivity disorder (ages 6-11) 100 mg orally once daily; may titrate in increments of 100 mg weekly to a maximum of 400 mg once daily.
Attention deficit hyperactivity disorder (ages 12-17) 200 mg orally once daily; may titrate after 1 week by 200 mg to a maximum of 400 mg once daily.
Attention deficit hyperactivity disorder (adults) 200 mg orally once daily; may titrate in increments of 200 mg weekly to a maximum of 600 mg once daily.
Severe renal impairment 100 mg once daily; titrate in weekly increments of 50-100 mg to a maximum of 200 mg once daily.
Contraindications
- History of hypersensitivity to methylphenidate or other components of JORNAY PM
- Concomitant treatment with monoamine oxidase (MAO) inhibitors, or within 14 days following discontinuation of an MAO inhibitor
- Concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, due to increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range
Adverse Reactions
Most common (>=5%) Any insomnia, decreased appetite, headache, vomiting, nausea, psychomotor hyperactivity, affect lability or mood swings
Serious Hypersensitivity reactions (angioedema, anaphylaxis), hypertensive crisis with MAO inhibitors, serious cardiac events, psychiatric adverse reactions, priapism, peripheral vasculopathy including Raynaud's phenomenon, long-term suppression of growth in pediatric patients
Postmarketing Pancytopenia, thrombocytopenia, angina pectoris, bradycardia, severe hepatic injury, rhabdomyolysis, convulsion, serotonin syndrome, hallucinations, mania, priapism, alopecia, Raynaud's phenomenon
Most common (>=5%) - Pediatric (ages 6-17) Somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, irritability
Most common (>=5%) - Adults Insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, constipation
Serious Suicidal thoughts and behaviors, blood pressure and heart rate increases, activation of mania or hypomania, somnolence and fatigue
Pharmacology
CNS stimulant; methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space, though the exact mode of therapeutic action in ADHD is not known.
Viloxazine is a selective norepinephrine reuptake inhibitor that inhibits the norepinephrine transporter and exhibits partial agonist activity at the serotonin 5-HT2C receptor; its mechanism of action in ADHD is thought to be through inhibiting norepinephrine reuptake.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jornay Pm
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (1/12)
Qelbree
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Jornay Pm
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (4/8)
Qelbree
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Jornay Pm
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Qelbree
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Jornay Pm.
No savings programs available for Qelbree.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Jornay PmView full Jornay Pm profile
QelbreeView full Qelbree profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.